IHE Posted The Biggest Loss Of All ETFs Today, Down 1%

Image of multicolor pills in blister pack
The iShares Dow Jones US Pharmaceuticals Index Fund (IHE) underperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a -0.98% one-day return and trailing the wider markets by a total of 1.35 percentage points.
NYSE:IHE January 20, 2017 6:05pm

So Much For The Bounce: IBB, Down 0.85%, Is Today’s Biggest ETF Loser

biotech-medical-pills
The iShares Nasdaq Biotechnology Index Fund (IBB) underperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a -0.84% one-day return and trailing the wider markets by a total of 0.47 percentage points.
NASDAQ:IBB January 19, 2017 6:53pm

IBB Bounces Back, Is Today’s Best Performing ETF On A Dollar Basis

biotech-white-pills
The iShares Nasdaq Biotechnology Index Fund (IBB) outperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a dollar basis, producing a +0.83% one-day return and outperforming the wider markets by a total of 0.61 percentage points.
NASDAQ:IBB January 18, 2017 5:08pm

Eli Lilly Buys Migraine Treatment Specialist CoLucid For $960M In Cash

eli-lilly-lly-logo
From StockNews.com: Eli Lilly and Co (NYSE:LLY) will acquire CoLucid Pharmaceuticals, a maker of a cutting edge migraine headache treatment, for $960 million, the two companies announced this morning.
ETF BASIC NEWS

The IBB Trailed All Major ETFs Today, With A Nearly 2% Drop

Arrow down
The iShares Nasdaq Biotechnology Index Fund (IBB) underperformed all other non-leveraged, non-inverse exchange traded products in the U.S. today on a percentage basis, producing a -1.96% one-day return and trailing the wider markets by a total of 1.61 percentage points.
NASDAQ:IBB January 17, 2017 5:16pm

Can Biotechs Recover From Trump’s Strong Condemnation?

biotech
From Zacks: The pharma and biotech industry is a victim of concerns over increased regulatory scrutiny on high drug prices over the past two years. The worries cooled down after Trump’s victory, and gave biotech stocks a shot in the arm.
NASDAQ:IBB January 13, 2017 9:13am

Healthcare And Biotech ETFs Continue Recovery As Money Pours In

biotech-white-pills
Conventional wisdom had Hillary Clinton as “bad” for the Healthcare space, specifically the Biotechs, given her bold statements on the campaign trail in regards to reining in prescription drug costs across the segment if she were to take office.
NYSE:XLV January 11, 2017 12:10pm

Ariad Pharmaceuticals Will Be Acquired For $5.2 Billion In Cash, 75% Premium

ariad-pharma-logo
From StockNews.com: Cancer treatment specialist Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has agreed to be acquired by Japanese biotech giant Takeda Pharmaceuticals for $24 per share in cash, in a blockbuster health care deal.
NASDAQ:ARIA January 9, 2017 9:07am

Biotech ETFs Could Be Poised For A New Rally

biotech-medical-pills
From Taki Tsaklanos: Recently, we spotted the potential of a breakdown in biotechnology stocks, see Biotechnology Stocks Have News For Investors: It is Now or Never. We warned readers to be on the safe side, as a breakdown scenario would be significant.
NASDAQ:IBB

This New Piece Of Legislation Could Be A Huge Boon For Pharma Companies

biotech-white-pills
From Sound Dollar Campaign: During the presidential campaign, the high price of prescription drugs became a blistering issue. At the same time, the Mylan/EpiPen scandal broke.
NYSE:XBI January 6, 2017 6:33am

Biotech Downturn Underscored By Lack Of New Drug Approvals

biotech-medical-pills
Following the astronomical gains of the previous several years, the biotech industry was hammered in 2016. Behind the decline was a huge downturn in the approval of new medicines.
NASDAQ:IBB January 2, 2017 10:31am

These Biotech Plays More Than Doubled This Year

biotech-white-pills
From Zacks: 2016 has not been a great year for biotech stocks which were under intense pressure with issues like increasing political and media focus on high price tags for drugs and the changing competitive scenario weighing on the sector.
NASDAQ:IBB December 22, 2016 11:18am

Biotechs Are In Danger Of Entering A Bear Market

biotech-white-pills
From Taki Tsaklanos: Biotechnology stocks have important news for investors. They are on the verge of a breakdown. In simple terms: if the biotechnology stock index goes slightly lower from today’s levels, the sector will be in deep trouble as it will enter a tactical bear market.
NASDAQ:IBB December 12, 2016 11:24am

Biotech Stocks Plunge As Trump Vows To Lower Drug Prices

donald-trump
The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) was on the decline this morning, after Donald Trump's TIME Person of the Year profile revealed that the president-elect likely won't be the bullish force for drug companies many thought he'd be.
NASDAQ:IBB December 7, 2016 9:18am

Recommended for You

Explore More from ETFDailyNews.com

Free Daily Newsletter

Get daily ETF insights from our market experts. Never miss another important market development again!

ETFDailyNews.com respects your privacy.

Best ETFs

We've rated and ranked nearly 2,000 ETFs and ETNs using our proprietary SMART Grade system.

View Top Rated ETFs

Best Categories

We've ranked dozens of ETF categories based on relative performance.

Best ETF Categories